Healthcare Services
Lung Cancer Liquid Biopsy Market

Lung Cancer Liquid Biopsy Market Size, Share, Trends, and Growth Forecasts 2025 - 2032

Lung Cancer Liquid Biopsy Market by Product (Instruments, Kits and Reagents, Software and Services), Technology (Multi-gene-parallel Analysis (NGS), Single Gene Analysis (PCR Microarrays)), End-user (Hospitals, Reference Laboratories, Others), Others and Regional Analysis For 2025 - 2032

ID: PMRREP35195

April 2025

180 Pages

Author : Vaishnavi Patil

Healthcare

Market Dynamics

Driver - Advances in Liquid Biopsy Technologies and Biomarker Discovery

Biomarkers such as microRNAs, mutated genes and proteins have been used in liquid biopsy to identify early cancer presence, progression, and response to therapy. Discovery of new biomarkers plays a pivotal role in improving the specificity and accuracy of liquid biopsy tests.

In line with these advancements, BioMark Diagnostics initiated enrollment for its pivotal lung cancer screening study in January 2023, combining BioMark’s metabolomics liquid biopsy test with radiomics and genetic biomarkers to enhance lung cancer screening accessibility and accuracy in Quebec.

Similarly, Freenome launched the PROACT LUNG clinical study in December 2023 to validate its blood test for early lung cancer detection. The test integrates lung cancer-specific biomarkers with cancer-common markers from Freenome’s multiomics platform. further contributing to the evolution of more precise and personalized approaches to lung cancer diagnosis.

Technologies such as NGS and PCR microarrays has further enabled deeper genetic profiling and comprehensive molecular information, allowing early detection of lung cancer and personalized treatment strategies. Funding and collaboration initiatives are undertaken by key players to develop new technologies, expanding the range of detectable genetic alterations.

Restraint - Limited Sensitivity of Biomarkers in Detecting Early-Stage Cancers

While liquid biopsy is highly demanding in cancer screening, detection, and treatment response, there are certain challenges associated with their usage such as limited sensitivity of biomarkers in detecting early-stage cancers. During early stages, the concentration of tumor-derived biomarkers, such as ctDNA or CTCs, are often very low and may produce insufficient amounts of genetic material into the blood, to be used for detection through liquid biopsy.

Complexity and diversity of tumor biology further adds to variability in biomarker expression, complicating the identification of early-stage cancers. Advancements in biomarker discovery and technology improve sensitivity, however, reaching required detection thresholds for early-stage cancers continues to be a significant hurdle, limiting the current potential of liquid biopsy as an early diagnostic tool.

Opportunity - Growing Demand for Liquid Biopsy as Companion Diagnostic Tool for Targeted Lung Cancer Treatment

Companion diagnostics (CDx) is a crucial tool gaining popularity in personalized medicine to identify lung cancer patients likely to benefit from specific targeted therapies such as EGFR inhibitors and ALK inhibitors. The capability of multigene panel assays of liquid biopsy has been approved as companion diagnostics and have been used in routine clinical settings.

Minimally invasive liquid-based CDx by liquid biopsy offers shorter turn-around time (TAT) enabling quicker, more efficient diagnostics, particularly beneficial in urgent cases. Moreover, reduction in NGS costs further supports liquid biopsy integration into routine clinical practice, making liquid biopsy an ideal CDx tool for lung cancer mutation screening.

Foundation Medicine, Inc. in November 2024, received U.S. FDA approval for FoundationOne®Liquid CDx as a companion diagnostic for TEPMETKO® (tepotinib) developed by EMD Serono, to identify patients with MET Exon 14 skipping alterations in non-small cell lung cancer (NSCLC).

This shift toward precision medicine presents a valuable opportunity for the lung cancer liquid biopsy market, fostering growth and innovation in cancer diagnostics.

Get Your CustomizationGet Your Customization

Category-wise Analysis

Product Insights

Consumables kits and reagents accounted for a revenue share of 71.2% in 2024 due to their recurrent use in the diagnostic procedures. Kits and reagents necessarily collect, process, and analyse samples, making them integral to the accuracy and efficiency of liquid biopsy tests. Growing adoption of liquid biopsy technologies for lung cancer detection is projected to augment demand for consumables such as test kits, reagents, and assay components.

Technology Insights

Globally, multi-gene-parallel analysis (NGS) dominated the technology category in 2024 with 75.2% market share due to their superior ability to analyze multiple genetic mutations simultaneously. NGS allows identification of wide genetic alterations such as point mutations, insertions, deletions, and gene amplifications, by providing comprehensive and high-throughput sequencing in lung cancer patients. NGS further enables precise targeting of therapies based on genetic profiles making them the preferred choice for both diagnostic and research applications.

lung cancer liquid biopsy market insights and key trends

Regional Insights and Trends

North America Lung Cancer Liquid Biopsy Market Trends

North America’s lung cancer liquid biopsy market accounted for 47.8% share in 2024. The region’s focus on widespread adoption of cutting-edge diagnostic technologies such as NGS and increased research investments fuels demand for liquid biopsy solutions. In February 2024, Roche invested USD 254 million in Freenome to advance its multiomics platform and develop blood tests for early cancer detection.

Growing prevalence of lung cancer in the U.S. significantly drive the U.S. lung cancer liquid biopsy market. As of 2025, nearly 226,650 new cases of lung cancer are estimated to be identified in the U.S. with 124,730 fatalities. 87% of these are categorized as non-small cell lung cancer (NSCLC) while small cell lung cancer (SCLC) represents 13%. Rising incidence coupled with increasing demand for less invasive diagnostic methods, positions the U.S. market for significant growth in lung cancer diagnosis and treatment.

Europe Lung Cancer Liquid Biopsy Market Trends

Europe is globally the second-leading generating a significant share of 28.6% in 2024. Significant investments are made in European region to accelerate developments in liquid biopsy technologies. Rising preference for non-invasive diagnostic methods and collaborative efforts between healthcare providers, academic institutions, and biotechnology companies further fuels demand for liquid biopsy solutions for lung cancer.

In March 2024, Guardant Health partnered with The Royal Marsden to expand the use of liquid biopsy technology, providing faster, more targeted treatments for lung cancer patients through the NHS England study.

Germany’s support for cutting-edge diagnostic methods and strong regulatory framework allow for faster integration of new technologies into clinical practice. Additionally, Germany’s reimbursement policies facilitate broader access to liquid biopsy diagnostics, thereby expanding the German lung cancer liquid biopsy market.

Likewise, in the U.K. the medical professional strongly emphasize early detection and personalized treatment. Increasing integration of National Health Service (NHS) into clinical pathways and U.K. government’s investment in precision medicine and its commitment to improving cancer care, including liquid biopsy supports market expansion. The combination of research breakthroughs, regulatory support, and patient demand positions Europe as a strong contender in the global liquid biopsy market for lung cancer.

Asia Pacific Lung Cancer Liquid Biopsy Market Trends

Asia Pacific is estimated to attain by 15.6% during the forecast period, driven by increasing incidence of lung cancer in the region, particularly in countries such as India, and China.

India's lung cancer liquid biopsy market is largely supported by the local biotech startups focusing on affordable, region-specific diagnostic solutions. Government initiatives aimed at enhancing early cancer detection and emphasizing cost-effective solutions are crucial factors accelerating liquid biopsy adoption in India. Johnson & Johnson launched a nationwide campaign, India Detects to Defeat, in November 2024, in collaboration with Amar Chitra Katha to assist in better understanding the risks, symptoms, and importance of early diagnosis and testing for lung cancer.

Request Free sampleRequest Free sample

Competitive Landscape

The global lung cancer liquid biopsy market is highly competitive with key players focusing on innovation and product launches through strategic research collaborations to offer advanced liquid biopsy solutions. Technological advancements, rising demand for non-invasive diagnostics, and personalized treatments drive the global market growth.

Key Industry Developments

In January 2025, Viz.ai partnered with Guardant Health to enhance lung cancer detection by combining AI and genomics through the Viz.ai One platform, ensuring patients receive timely, personalized, and effective care.
In December 2024, Guardant Health teamed up with Boehringer Ingelheim to seek regulatory approval and commercialization of the Guardant360® CDx liquid biopsy as a companion diagnostic for zongertinib, a targeted tyrosine kinase inhibitor for non-small cell lung cancer (NSCLC).
In April 2024, City of Hope partnered with DELFI Diagnostics to enhance lung cancer screening in underserved Los Angeles communities. Funded by an American Cancer Society grant, the study utilizes DELFI's FirstLook Lung blood test to increase screening rates.

Companies Covered in Lung Cancer Liquid Biopsy Market

S Bio-Rad Laboratories, Inc.
Agilent Technologies, Inc.
Oncocyte Corporation
NeoGenomics Laboratories
Lepu Medical Technology(Beijing)Co.,Ltd
QIAGEN
Thermo Fisher Scientific Inc.
Illumina, Inc.
F. Hoffmann-La Roche Ltd
Sysmex Corporation
BioView
Guardant Health, Inc
SOPHiA GENETICS
BioMark Diagnostics
DELFI Diagnostics, Inc.
Freenome Holdings, Inc.
Foresight Diagnostics, Inc.
Foundation Medicine, Inc.
Pillar Biosciences, Inc.
Caris Life Sciences

Frequently Asked Questions

The global market is set to reach US$ 824.7 Mn in 2025.

By product, consumables kits and reagents is projected to dominate the global market in 2025.

The industry is estimated to rise at a CAGR of 12.7% through 2032.

North America is projected to hold the largest share of the industry in 2025.

Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., QIAGEN, Thermo Fisher Scientific Inc., Illumina, Inc., F. Hoffmann-La Roche Ltd are a few leading players.

Top-Down Market Sizing	Bottom-Up Market Sizing
Universe Definition: Total global/regional market identification	Unit Economics: Average transaction values, purchase frequencies, customer lifecycle
Segmentation Filters: Geographic, demographic, and behavioral constraints	Customer Segmentation: Detailed buyer persona development and sizing
Market Share Analysis: Competitive landscape assessment and share allocation	Penetration Analysis: Market penetration rates by segment and geography
Growth Rate Application: Historical trends and forward-looking growth assumptions	Scaling Methodology: Extrapolation techniques with confidence intervals

Interested in this report?

Request customization, ask for expert consulting, access a sample report, or simply express your interest—our team will assist you with the right insights and solutions.

Request Custom VersionRequest Custom Version

Clients

Media Citation

Get In Touch

Loading page data

Please wait a moment

Executive Summary
1. Global Lung Cancer Liquid Biopsy Snapshot, 2025 and 2032
2. Market Opportunity Assessment, 2024 - 2032, US$ Mn
3. Key Market Trends
4. Future Market Projections
5. Premium Market Insights
6. Industry Developments and Key Market Events
7. PMR Analysis and Recommendations
Market Overview
1. Market Scope and Definition
2. Market Dynamics
  1. Drivers
  2. Restraints
  3. Opportunity
  4. Key Trends
3. Macro-Economic Factors
  1. Global Sectorial Outlook
  2. Global GDP Growth Outlook
4. COVID-19 Impact Analysis
5. Forecast Factors - Relevance and Impact
Value Added Insights
1. Product Adoption Analysis
2. Disease Epidemiology
3. Regulatory Landscape
4. List of Suppliers
5. Porter’s Five Forces Analysis
6. PESTLE Analysis
7. Promotional Strategies, By Key Players
Global Lung Cancer Liquid Biopsy Outlook
1. Key Highlights
  1. Market Size (US$ Mn) and Y-o-Y Growth
  2. Absolute $ Opportunity
2. Market Size (US$ Mn) Analysis and Forecast
  1. Historical Market Size (US$ Mn) Analysis, 2019-2023
  2. Current Market Size (US$ Mn) Analysis and Forecast, 2024 - 2032
3. Global Lung Cancer Liquid Biopsy Outlook: Product
  1. Introduction / Key Findings
  2. Historical Market Size (US$ Mn) Analysis, By Product, 2019 - 2023
  3. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2024 - 2032
    1. Instruments
    2. Kits and Reagents
    3. Software and Services
  4. Market Attractiveness Analysis: Product
4. Global Lung Cancer Liquid Biopsy Outlook: Technology
  1. Introduction / Key Findings
  2. Historical Market Size (US$ Mn), By Technology, 2019 - 2023
  3. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2024 - 2032
    1. Multi-gene-parallel Analysis (NGS)
    2. Single Gene Analysis (PCR Microarrays)
  4. Market Attractiveness Analysis: Technology
5. Global Lung Cancer Liquid Biopsy Outlook: Biomarker
  1. Introduction / Key Findings
  2. Historical Market Size (US$ Mn), By Biomarker, 2019 - 2023
  3. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2024 - 2032
    1. Cell-free DNA (cfDNA)
    2. Circulating tumor DNA (ctDNA)
    3. Extracellular Vesicles (EVs)
    4. Circulating Tumor Cells (CTC)
    5. Others
  4. Market Attractiveness Analysis: Biomarker
6. Global Lung Cancer Liquid Biopsy Outlook: Indication
  1. Introduction / Key Findings
  2. Historical Market Size (US$ Mn), By Indication, 2019 - 2023
  3. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2024 - 2032
    1. Small Cell Lung Cancer (SCLC)
    2. Non-Small Cell Lung Cancer (NSCLC)
  4. Market Attractiveness Analysis: Indication
7. Global Lung Cancer Liquid Biopsy Outlook: Sample
  1. Introduction / Key Findings
  2. Historical Market Size (US$ Mn), By Sample, 2019 - 2023
  3. Current Market Size (US$ Mn) Analysis and Forecast, By Sample, 2024 - 2032
    1. Blood
    2. Cerebrospinal Fluid (CSF)
    3. Plasma
    4. Serum
    5. Others
  4. Market Attractiveness Analysis: Sample
8. Global Lung Cancer Liquid Biopsy Outlook: End User
  1. Introduction / Key Findings
  2. Historical Market Size (US$ Mn), By End User, 2019 - 2023
  3. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024 - 2032
    1. Hospitals
    2. Reference Laboratories
    3. Academic & Research Institutes
    4. Others
  4. Market Attractiveness Analysis: End User
Global Lung Cancer Liquid Biopsy Outlook: Region
1. Key Highlights
2. Historical Market Size (US$ Mn) Analysis, By Region, 2019 - 2023
3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2024 - 2032
  1. North America
  2. Europe
  3. East Asia
  4. South Asia and Oceania
  5. Latin America
  6. Middle East & Africa
4. Market Attractiveness Analysis: Region
North America Lung Cancer Liquid Biopsy Outlook
1. Key Highlights
2. Historical Market Size (US$ Mn) Analysis, By Market, 2019 - 2023
  1. By Country
  2. By Product
  3. By Technology
  4. By Biomarker
  5. By Indication
  6. By Sample
  7. By End User
3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024 - 2032
  1. U.S.
  2. Canada
4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2024 - 2032
  1. Instruments
  2. Kits and Reagents
  3. Software and Services
5. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2024 - 2032
  1. Multi-gene-parallel Analysis (NGS)
  2. Single Gene Analysis (PCR Microarrays)
6. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2024 - 2032
  1. Cell-free DNA (cfDNA)
  2. Circulating tumor DNA (ctDNA)
  3. Extracellular Vesicles (EVs)
  4. Circulating Tumor Cells (CTC)
  5. Others
7. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2024 - 2032
  1. Small Cell Lung Cancer (SCLC)
  2. Non-Small Cell Lung Cancer (NSCLC)
8. Current Market Size (US$ Mn) Analysis and Forecast, By Sample, 2024 - 2032
  1. Blood
  2. Cerebrospinal Fluid (CSF)
  3. Plasma
  4. Serum
  5. Others
9. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024 - 2032
  1. Hospitals
  2. Reference Laboratories
  3. Academic & Research Institutes
  4. Others
10. Market Attractiveness Analysis
Europe Lung Cancer Liquid Biopsy Outlook
1. Key Highlights
2. Historical Market Size (US$ Mn) Analysis, By Market, 2019 - 2023
  1. By Country
  2. By Product
  3. By Technology
  4. By Biomarker
  5. By Indication
  6. By Sample
  7. By End User
3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024 - 2032
  1. Germany
  2. France
  3. U.K.
  4. Italy
  5. Spain
  6. Russia
  7. Türkiye
  8. Rest of Europe
4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2024 - 2032
  1. Instruments
  2. Kits and Reagents
  3. Software and Services
5. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2024 - 2032
  1. Multi-gene-parallel Analysis (NGS)
  2. Single Gene Analysis (PCR Microarrays)
6. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2024 - 2032
  1. Cell-free DNA (cfDNA)
  2. Circulating tumor DNA (ctDNA)
  3. Extracellular Vesicles (EVs)
  4. Circulating Tumor Cells (CTC)
  5. Others
7. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2024 - 2032
  1. Small Cell Lung Cancer (SCLC)
  2. Non-Small Cell Lung Cancer (NSCLC)
8. Current Market Size (US$ Mn) Analysis and Forecast, By Sample, 2024 - 2032
  1. Blood
  2. Cerebrospinal Fluid (CSF)
  3. Plasma
  4. Serum
  5. Others
9. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024 - 2032
  1. Hospitals
  2. Reference Laboratories
  3. Academic & Research Institutes
  4. Others
10. Market Attractiveness Analysis
East Asia Lung Cancer Liquid Biopsy Outlook
1. Key Highlights
2. Historical Market Size (US$ Mn) Analysis, By Market, 2019 - 2023
  1. By Country
  2. By Product
  3. By Technology
  4. By Biomarker
  5. By Indication
  6. By Sample
  7. By End User
3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024 - 2032
  1. China
  2. Japan
  3. South Korea
4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2024 - 2032
  1. Instruments
  2. Kits and Reagents
  3. Software and Services
5. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2024 - 2032
  1. Multi-gene-parallel Analysis (NGS)
  2. Single Gene Analysis (PCR Microarrays)
6. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2024 - 2032
  1. Cell-free DNA (cfDNA)
  2. Circulating tumor DNA (ctDNA)
  3. Extracellular Vesicles (EVs)
  4. Circulating Tumor Cells (CTC)
  5. Others
7. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2024 - 2032
  1. Small Cell Lung Cancer (SCLC)
  2. Non-Small Cell Lung Cancer (NSCLC)
8. Current Market Size (US$ Mn) Analysis and Forecast, By Sample, 2024 - 2032
  1. Blood
  2. Cerebrospinal Fluid (CSF)
  3. Plasma
  4. Serum
  5. Others
9. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024 - 2032
  1. Hospitals
  2. Reference Laboratories
  3. Academic & Research Institutes
  4. Others
10. Market Attractiveness Analysis
South Asia & Oceania Lung Cancer Liquid Biopsy Outlook
1. Key Highlights
2. Historical Market Size (US$ Mn) Analysis, By Market, 2019 - 2023
  1. By Country
  2. By Product
  3. By Technology
  4. By Biomarker
  5. By Indication
  6. By Sample
  7. By End User
3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024 - 2032
  1. India
  2. Southeast Asia
  3. ANZ
  4. Rest of South Asia & Oceania
4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2024 - 2032
  1. Instruments
  2. Kits and Reagents
  3. Software and Services
5. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2024 - 2032
  1. Multi-gene-parallel Analysis (NGS)
  2. Single Gene Analysis (PCR Microarrays)
6. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2024 - 2032
  1. Cell-free DNA (cfDNA)
  2. Circulating tumor DNA (ctDNA)
  3. Extracellular Vesicles (EVs)
  4. Circulating Tumor Cells (CTC)
  5. Others
7. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2024 - 2032
  1. Small Cell Lung Cancer (SCLC)
  2. Non-Small Cell Lung Cancer (NSCLC)
8. Current Market Size (US$ Mn) Analysis and Forecast, By Sample, 2024 - 2032
  1. Blood
  2. Cerebrospinal Fluid (CSF)
  3. Plasma
  4. Serum
  5. Others
9. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024 - 2032
  1. Hospitals
  2. Reference Laboratories
  3. Academic & Research Institutes
  4. Others
10. Market Attractiveness Analysis
Latin America Lung Cancer Liquid Biopsy Outlook
1. Key Highlights
2. Historical Market Size (US$ Mn) Analysis, By Market, 2019 - 2023
  1. By Country
  2. By Product
  3. By Technology
  4. By Biomarker
  5. By Indication
  6. By Sample
  7. By End User
3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024 - 2032
  1. Brazil
  2. Mexico
  3. Rest of Latin America
4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2024 - 2032
  1. Instruments
  2. Kits and Reagents
  3. Software and Services
5. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2024 - 2032
  1. Multi-gene-parallel Analysis (NGS)
  2. Single Gene Analysis (PCR Microarrays)
6. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2024 - 2032
  1. Cell-free DNA (cfDNA)
  2. Circulating tumor DNA (ctDNA)
  3. Extracellular Vesicles (EVs)
  4. Circulating Tumor Cells (CTC)
  5. Others
7. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2024 - 2032
  1. Small Cell Lung Cancer (SCLC)
  2. Non-Small Cell Lung Cancer (NSCLC)
8. Current Market Size (US$ Mn) Analysis and Forecast, By Sample, 2024 - 2032
  1. Blood
  2. Cerebrospinal Fluid (CSF)
  3. Plasma
  4. Serum
  5. Others
9. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024 - 2032
  1. Hospitals
  2. Reference Laboratories
  3. Academic & Research Institutes
  4. Others
10. Market Attractiveness Analysis
Middle East & Africa Lung Cancer Liquid Biopsy Outlook
1. Key Highlights
2. Historical Market Size (US$ Mn) Analysis, By Market, 2019 - 2023
  1. By Country
  2. By Product
  3. By Technology
  4. By Biomarker
  5. By Indication
  6. By Sample
  7. By End User
3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024 - 2032
  1. GCC Countries
  2. Egypt
  3. South Africa
  4. Northern Africa
  5. Rest of Middle East & Africa
4. Current Market Size (US$ Mn) Analysis and Forecast, By Product, 2024 - 2032
  1. Instruments
  2. Kits and Reagents
  3. Software and Services
5. Current Market Size (US$ Mn) Analysis and Forecast, By Technology, 2024 - 2032
  1. Multi-gene-parallel Analysis (NGS)
  2. Single Gene Analysis (PCR Microarrays)
6. Current Market Size (US$ Mn) Analysis and Forecast, By Biomarker, 2024 - 2032
  1. Cell-free DNA (cfDNA)
  2. Circulating tumor DNA (ctDNA)
  3. Extracellular Vesicles (EVs)
  4. Circulating Tumor Cells (CTC)
  5. Others
7. Current Market Size (US$ Mn) Analysis and Forecast, By Indication, 2024 - 2032
  1. Small Cell Lung Cancer (SCLC)
  2. Non-Small Cell Lung Cancer (NSCLC)
8. Current Market Size (US$ Mn) Analysis and Forecast, By Sample, 2024 - 2032
  1. Blood
  2. Cerebrospinal Fluid (CSF)
  3. Plasma
  4. Serum
  5. Others
9. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024 - 2032
  1. Hospitals
  2. Reference Laboratories
  3. Academic & Research Institutes
  4. Others
10. Market Attractiveness Analysis
Competition Landscape
1. Market Share Analysis, 2024
2. Market Structure
  1. Competition Intensity Mapping By Market
  2. Competition Dashboard
3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  1. Bio-Rad Laboratories, Inc.
    1. Overview
    2. Segments and Products
    3. Key Financials
    4. Market Developments
    5. Market Strategy
  2. Agilent Technologies, Inc.
  3. Oncocyte Corporation
  4. NeoGenomics Laboratories
  5. Lepu Medical Technology(Beijing)Co.,Ltd
  6. QIAGEN
  7. Thermo Fisher Scientific Inc.
  8. Illumina, Inc.
  9. F. Hoffmann-La Roche Ltd
  10. Sysmex Corporation
  11. BioView
  12. Guardant Health, Inc
  13. SOPHiA GENETICS
  14. BioMark Diagnostics
  15. DELFI Diagnostics, Inc.
  16. Freenome Holdings, Inc.
  17. Foresight Diagnostics, Inc.
  18. Foundation Medicine, Inc.
  19. Pillar Biosciences, Inc.
  20. Caris Life Sciences
Appendix
1. Research Methodology
2. Research Assumptions
3. Acronyms and Abbreviations

Global Market Attribute	Key Insights
Lung Cancer Liquid Biopsy Market Size (2025E)	US$ 824.7 Mn
Market Value Forecast (2032F)	US$ 1,900.5 Mn
Projected Growth (CAGR 2025 to 2032)	12.7%
Historical Market Growth (CAGR 2019 to 2024)	9.3%

Attributes	Details
Historical Data/Actuals	2019 - 2024
Forecast Period	2025 - 2032
Market Analysis Units	Value: US$ Mn/Bn Volume: Units
Geographical Coverage	North America Europe East Asia South Asia and Oceania Middle East and Africa Latin America
Segmental Coverage	Product Technology Biomarker Indication Sample End-user Region
Competitive Analysis	S Bio-Rad Laboratories, Inc. Agilent Technologies, Inc. Oncocyte Corporation NeoGenomics Laboratories Lepu Medical Technology(Beijing)Co.,Ltd QIAGEN Thermo Fisher Scientific Inc. Illumina, Inc. F. Hoffmann-La Roche Ltd Sysmex Corporation BioView Guardant Health, Inc SOPHiA GENETICS BioMark Diagnostics DELFI Diagnostics, Inc. Freenome Holdings, Inc. Foresight Diagnostics, Inc. Foundation Medicine, Inc. Pillar Biosciences, Inc. Caris Life Sciences
Report Highlights	Market Forecast and Trends Competitive Intelligence & Share Analysis Growth Factors and Challenges Strategic Growth Initiatives Pricing Analysis & Technology Roadmap Future Opportunities and Revenue Pockets Industry Market Analysis Tools
Customization and Pricing	Available upon request

Global Market Attribute	Key Insights
Lung Cancer Liquid Biopsy Market Size (2025E)	US$ 824.7 Mn
Market Value Forecast (2032F)	US$ 1,900.5 Mn
Projected Growth (CAGR 2025 to 2032)	12.7%
Historical Market Growth (CAGR 2019 to 2024)	9.3%

Attributes	Details
Historical Data/Actuals	2019 - 2024
Forecast Period	2025 - 2032
Market Analysis Units	Value: US$ Mn/Bn Volume: Units
Geographical Coverage	North America Europe East Asia South Asia and Oceania Middle East and Africa Latin America
Segmental Coverage	Product Technology Biomarker Indication Sample End-user Region
Competitive Analysis	S Bio-Rad Laboratories, Inc. Agilent Technologies, Inc. Oncocyte Corporation NeoGenomics Laboratories Lepu Medical Technology(Beijing)Co.,Ltd QIAGEN Thermo Fisher Scientific Inc. Illumina, Inc. F. Hoffmann-La Roche Ltd Sysmex Corporation BioView Guardant Health, Inc SOPHiA GENETICS BioMark Diagnostics DELFI Diagnostics, Inc. Freenome Holdings, Inc. Foresight Diagnostics, Inc. Foundation Medicine, Inc. Pillar Biosciences, Inc. Caris Life Sciences
Report Highlights	Market Forecast and Trends Competitive Intelligence & Share Analysis Growth Factors and Challenges Strategic Growth Initiatives Pricing Analysis & Technology Roadmap Future Opportunities and Revenue Pockets Industry Market Analysis Tools
Customization and Pricing	Available upon request

Lung Cancer Liquid Biopsy Market Size, Share, Trends, and Growth Forecasts 2025 - 2032

Lung Cancer Liquid Biopsy Market by Product (Instruments, Kits and Reagents, Software and Services), Technology (Multi-gene-parallel Analysis (NGS), Single Gene Analysis (PCR Microarrays)), End-user (Hospitals, Reference Laboratories, Others), Others and Regional Analysis For 2025 - 2032